- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Talquetamab, Daratumumab
- Drug
- Lead sponsor
- Larysa Sanchez
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Total Marrow Irradiation, Autologous Transplant, Melphalan, Filgrastim (G-CSF)
- Radiation · Procedure · Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Neratinib, Capecitabine
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 12
- States / cities
- Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
- Drug · Biological · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- Genotropin, somatrogon
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 18
- States / cities
- Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
- Conditions
- Pregnancy, Unexplained Infertility
- Interventions
- Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
- Conditions
- Leukemia
- Interventions
- LY2090314
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • Durham, North Carolina + 1 more
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
- Biological · Other · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Migraine
- Interventions
- Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
- Drug
- Lead sponsor
- Nova Pneuma Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO5024048
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
- Conditions
- Infections, Bacterial
- Interventions
- Gepotidacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- La Mesa, California
- Conditions
- Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
- Interventions
- GTB-5550
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Shigella Infection, Enterotoxigenic Escherichia Coli Infection
- Interventions
- strain CVD 1208S-122, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity
- Interventions
- NNC0519-0130, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 49
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
- Conditions
- CoronaVirus Disease-2019 (COVID-19)
- Interventions
- ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine, Scopolamine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
- Interventions
- Afimetoran, Placebo
- Drug
- Lead sponsor
- Beeline Medicines Corporation
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • DeBary, Florida • Missoula, Montana
- Conditions
- Diabetic Macular Edema (DME), Pars Plana Vitrectomy
- Interventions
- SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bladder Cancer
- Interventions
- Qapzola, Placebo
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx
- Drug · Diagnostic Test
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
- Conditions
- Environmental Exposure
- Interventions
- Cholestyramine, Centrum
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
- Interventions
- Telephone reminder, Text Message reminder
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 749 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Rochester, New York
- Conditions
- Osteoarthritis
- Interventions
- Meloxicam Test Capsules, Placebo Capsules
- Drug
- Lead sponsor
- Iroko Pharmaceuticals, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more